对LNP制造的预制膀方法提高了视网膜mRNA的传递
Yulia Eygeris1, Michael I Henderson1, Allison G Curtis2
1Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, OR, 97201, USA.
Small (Weinheim an der Bergstrasse, Germany)
|May 13, 2024
概括
预制的囊泡脂质纳米颗粒 (PFV-LNPs) 增强了mRNA向视网膜的传递,改善了视网膜耐受性,而不会牺牲基因编辑功效. 这种新的配方工艺为核酸疗法提供了更安全的替代方案.
科学领域:
- 生物技术是生物技术.
- 眼科医生 眼科 眼科
- 基因治疗 基因治疗
背景情况:
- 核酸在基于脂质的纳米粒子 (LNP) 中的完整封装传统上被认为是成功分娩的必要条件.
- 这种封装保护mRNA免受降解,并有助于细胞吸收.
研究的目的:
- 调查预制囊泡脂质纳米颗粒 (PFV-LNP) 方法用于将mRNA输送到视网膜的疗效.
- 评估PFV-LNP中的表面mRNA定位是否与传统LNP相比影响传递效率和耐受性.
主要方法:
- 使用无溶剂混合工艺制定PFV-LNP,导致表面mRNA局部化.
- 在视网膜色素表皮和光受体中评估了mRNA传递和基因编辑效率 in vivo (小鼠,非人类灵长类动物) 和 in vitro (人类视网膜器官).
- 在Ai9记者小鼠模型中评估了视网膜耐受性.
主要成果:
- 与传统的LNP相比,PFV-LNP在mRNA向视网膜传递方面表现出高达50%的改善,尽管封装效率低.
- 在多种物种和模型中观察到mRNA和基因编辑器的成功传递.
- 虽然PFV-LNP的基因编辑水平与传统LNP相比,但显著改善了视网膜耐受性.
结论:
- 这种LNP的配方过程极大地影响了mRNA转染和基因编辑的结果.
- 在不影响疗效的情况下,PFV-LNP为增强基于LNP的核酸疗法的安全性提供了一个有希望的策略,用于视网膜应用.
相关概念视频
Chromatin Structure Regulates pre-mRNA Processing
In eukaryotic cells, nascent mRNA transcripts need to undergo many post-transcriptional modifications to reach the cell cytoplasm and translate into functional proteins. For a long time, transcription and pre-mRNA processing were considered two independent events that occur sequentially in the cell. However, it has now been well established that transcription and pre-mRNA processing are two simultaneous processes that are precisely regulated inside the cell.
The chromatin structure, especially...
The chromatin structure, especially...
lncRNA - Long Non-coding RNAs
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...


